HDAC6
Protein deacetylase HDAC6
As of the edition of 20 October 2026, HDAC6 (protein deacetylase HDAC6, UniProt Q9UBN7) has 9 drugs tested at it and 10 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UBN7
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 22
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Heart and blood vessels; Nervous system; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 288
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vorinostat | Marketed | Phase 3 | Ends 2027 |
| Ricolinostat | Stopped | Phase 2 | none listed |
| Citarinostat | Stopped | Phase 1 | none listed |
| Jbi-802 free base | Active | Phase 2 | none listed |
| CKD-506 | Status not established | Phase 2 | none listed |
| KA-2507 | Stopped | Phase 2 | none listed |
| PKN605 | Active | Phase 2 | none listed |
| CKD-504 | Went quiet | Phase 1 | none listed |
| MTX110 | Stopped | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 4 |
| Undetermined | 2 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Bristol Myers Squibb | Route A |
| 3E-Regenacy Pharmaceuticals | Route A |
The other 7 companies at HDAC6
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at HDAC6, ranked, with the facts behind eachRequest access. Nothing is shown until you do.